Literature DB >> 9853786

Health care expenditure on schizophrenia patients in Belgium.

M De Hert1, E Thys, J Boydens, P Gilis, K Kesteloot, L Verhaegen, J Peuskens.   

Abstract

Schizophrenia generates a great deal of cost and burden. The aim of this study was to assess the direct costs for schizophrenia patients receiving standard treatment in different settings in Belgium. Costs were calculated for patients and for the Belgian insurance system. Data from Belgium's largest sickness fund were used to estimate health expenditures for all schizophrenia patients in Belgium. The mean direct treatment cost was $12,050 per patient per year, or $304 million for all schizophrenia patients per year. This cost constitutes 1.9 percent of the Belgian Government's total health expenditure. Government expenditure per schizophrenia patient is 10 times that of an average citizen.

Entities:  

Mesh:

Year:  1998        PMID: 9853786     DOI: 10.1093/oxfordjournals.schbul.a033346

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  13 in total

1.  Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

Authors:  Diana De Graeve; Ann Smet; Angelika Mehnert; Sue Caleo; Houda Miadi-Fargier; Guillermo Jasso Mosqueda; Damien Lecompte; Joseph Peuskens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 3.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

5.  Direct costs of schizophrenia in Italian community psychiatric services.

Authors:  L Garattini; C Rossi; F Tediosi; C Cornaggia; G Covelli; C Barbui; F Parazzini
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

8.  Perspective from an NGO.

Authors:  R Thara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

9.  Pharmacological treatment of ambulatory schizophrenic patients in Belgium.

Authors:  L Hanssens; M De Hert; M Wampers; J-Y Reginster; J Peuskens
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-05-30

10.  The cost of schizophrenia in Japan.

Authors:  Mitsuhiro Sado; Ataru Inagaki; Akihiro Koreki; Martin Knapp; Lee Andrew Kissane; Masaru Mimura; Kimio Yoshimura
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-30       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.